Vanda Pharmaceuticals Inc.
HETLIOZ
jet lag disorder
Resolved
181days ago
FDA decision · Jan 7, 2026
What's at stake
An FDA complete response letter on HETLIOZ for jet lag disorder is in focus around Jan 7, 2026.
Primary source
· SEC 8-K
verified 13h ago
“On January 7, 2026, Vanda received a letter from the FDA stating that, following this re-review, it had concluded that the sNDA cannot be approved in its current form.”